The short version of hGH fragment fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-11-22. Anything still debated is marked as such rather than presented as settled.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
The start of the reaction, and indeed of the entire electron chain, is the binding of a NADH molecule to complex I and the donation of two electrons. The electrons enter complex I via a prosthetic group attached to the complex, flavin mononucleotide (FMN). The addition of electrons to FMN converts it to its reduced form, FMNH2. The electrons are then transferred through a series of iron–sulfur clusters: the second kind of prosthetic group present in the complex. There are both [2Fe–2S] and [4Fe–4S] iron–sulfur clusters in complex I. As the electrons pass through this complex, four protons are pumped from the matrix into the intermembrane space. Exactly how this occurs is unclear, but it seems to involve conformational changes in complex I that cause the protein to bind protons on the N-side of the membrane and release them on the P-side of the membrane. Finally, the electrons are transferred from the chain of iron–sulfur clusters to a ubiquinone molecule in the membrane. Reduction of ubiquinone also contributes to the generation of a proton gradient, as two protons are taken up from the matrix as it is reduced to ubiquinol (QH2).
=== Spread of Enlightenment ideals === Other factors may include Enlightenment thinking and the examples of the Atlantic Revolutions. The Enlightenment spurred the desire for social and economic reform to spread throughout Spanish America and the Iberian Peninsula. Ideas about free trade and physiocratic economics were raised by the Enlightenment in Spain and spread to the overseas empire and a homegrown Spanish American Enlightenment. The political reforms implemented and the many constitutions written both in Spain and throughout the Spanish world during the wars of independence were influenced by these factors.
=== D-ribose L-cysteine === D-ribose-L-cysteine (riboceine) is a chemical compound developed as a cysteine prodrug intended to increase endogenous production of glutathione, a naturally occurring intracellular antioxidant. Structurally, it consists of D-ribose, a pentose sugar involved in cellular energy metabolism, chemically bound to L-cysteine, an amino acid required for glutathione biosynthesis.
== External links == Clinical trial number NCT03349060 for "Study to Evaluate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-1)" at ClinicalTrials.gov Clinical trial number NCT03575871 for "Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis (JADE Mono-2)" at ClinicalTrials.gov Clinical trial number NCT03720470 for "Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy (JADE Compare)" at ClinicalTrials.gov
Sources: en.wikipedia.org
People in Sanlúcar historically worked primarily in agriculture (mainly viticulture) and fishing (especially for the famous Sanlúcar prawn). These two occupations were naturally concentrated in different parts of the town, and until the modernizing trends of the last few decades, there were marked distinctions between the people living in each area. People living near the sea, in the area known as Bajo de Guía, were almost exclusively dedicated to fishing. Now these same people combine fishing with managing restaurants that rely on fresh fish and shellfish for their menus. People living in the higher elevations away from the sea, in a part of the town known as the Barrio Alto, formerly dedicated themselves exclusively to agriculture. However, with the advent of mechanisation this sector requires less manpower throughout the year, and most farm workers now work only seasonally during the grape harvest, in the so-called "sherry triangle". The centre of Sanlúcar developed as a commercial hub, with a cityscape of intermixed historic buildings (monasteries, churches, etc.) and more modern ones. This part of the city developed at the beginning of the 20th century as the neighbourhood of the bourgeoisie and the aristocracy. Sanlúcar was then a popular beach resort; presently the people living in this area are generally linked to local wine-making interests and the tourist industry.
== Upholstery filling == Buckwheat hulls are used as filling for a variety of upholstered goods, including pillows. The hulls are durable and do not insulate or reflect heat as much as synthetic filling. They are sometimes marketed as an alternative natural filling to feathers for those allergic to feathers. However, medical studies to measure the health effects of pillows manufactured with unprocessed and uncleaned hulls concluded that such pillows contain higher levels of a potential allergen that may trigger asthma in susceptible individuals than do synthetic-filled pillows.
There is no adequate level, recommended daily amount or tolerable upper limit for trans fats. This is because any incremental increase in trans fat intake increases the risk of coronary artery disease. Despite this concern, the NAS dietary recommendations have not included eliminating trans fat from the diet. This is because trans fat is naturally present in many animal foods in trace quantities, and thus its removal from ordinary diets might introduce undesirable side effects and nutritional imbalances. The NAS has, thus, "recommended that trans fatty acid consumption be as low as possible while consuming a nutritionally adequate diet". Like the NAS, the WHO has tried to balance public health goals with a practical level of trans fat consumption, recommending in 2003 that trans fats be limited to less than 1% of overall energy intake.
Sources: en.wikipedia.org
=== From human single-domain antibodies === Humans occasionally produce single domain antibodies by the random creation of a stop codon in the light chain. Human single-domain antibodies targeting various tumor antigens including mesothelin, GPC2 and GPC3 were isolated by phage display. The HN3 human single-domain antibodies have been used to create immunotoxins and chimeric antigen receptor (CAR) T cells for treating liver cancer. Blocking the Wnt binding domain of GPC3 by the HN3 human single-domain antibody inhibits Wnt activation in liver cancer cells.
The sisters also released a book, Kardashian Konfidential, in November 2010. In February 2011, Kardashian and her husband released a unisex fragrance called "Unbreakable." In May 2011, Kardashian and her sisters announced the release of their first novel. Prior to publication, the sisters requested help with naming their book. The winner was offered a cameo appearance in the novel. In July 2011, it was announced that the winning title was Dollhouse. In October 2012, Kardashian and Odom released a second unisex fragrance, "Unbreakable Joy," inspired by the holiday season. Kardashian's radio show, The Mix Up With Khloé Kardashian Odom, was a "one-hour, commercial-free show where Kardashian will take requests, chat with her celebrity friends, and more during the Mavericks' season while she's in Dallas with her husband Lamar Odom." It aired on January 30, 2012. She later made an appearance on the MTV television series Punk'd with Kelly Osbourne and Miley Cyrus in February 2012. In October 2012, Kardashian and Mario Lopez were confirmed as the co-hosts of the second season of the American version of The X Factor. It was confirmed on April 22, 2013, that Kardashian will not return to co-host The X Factor for its third season. On March 26, 2014, E! announced a Keeping Up with the Kardashians spin-off series titled Kourtney & Khloé Take the Hamptons. The Hamptons follows Kourtney, Khloé, and Scott Disick as they relocate to The Hamptons while the girls work on the New York Dash store plus open a pop-up store.
== Politics == The company spends approximately $10 million per year on lobbying in the United States. Political contributions have mostly been to individuals and organizations associated with the Democratic Party. The company is a member of many industry advocacy groups and sponsors many industry events.
The full-length version with an ATA start, which is transcribed at only 1% the level of other animals with the normal ATG start. A severely truncated version beginning at methionine-76 (Met-76). This version has no predicted signal peptide required for transport out of cytoplasm. A mass spectrometry study reported irisin levels ~3 ng/ml in human plasma, a level on par with other key human hormones, such as insulin. The same study reports that the main form in plasma is the ATA form, as expected for signal peptide presence. There is no comparable study of irisin levels in other animals. In a more recent study, Witmer et al. provide complementary genomic and molecular evidence to demonstrate that Fndc5 (irisin myokine precursor protein) is translated in humans and mice from an overlooked upstream ATG start codon. These findings lend further support to the likely existence of irisin in humans, revealing more plausible mechanisms of Fndc5 protein translation and processing as compared to possible expression from an inefficient mutated ATA start codon.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.